Androgen Receptor Status in Triple Negative Breast Cancer: Does It Correlate with Clinicopathological Characteristics?

References

• Giovannelli P, Di Donato M, Galasso G, et al. The androgen receptor in breast cancer. Front Endocrinol. 2018;9(492). doi:10.3389/fendo.2018.00492
   PubMedGoogle Scholar
• Akram M, Iqbal M, Daniyal M, Khan AU. Awareness and current knowledge of breast cancer. Biol Res. 2017;50(1). doi:10.1186/s40659-017-0140-9
   PubMedGoogle Scholar
• Feng Y, Spezia M, Huang S, et al. Breast cancer development and progression: risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;5:77–106. doi:10.1016/j.gendis.2018.05.001
   PubMed Web of Science ®Google Scholar
• Mehanna J, Haddad FG, Eid R, Lambertini M, Kourie HR. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health. 2019;11:431–437. doi:10.2147/IJWH.S178349
   PubMed Web of Science ®Google Scholar
• Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer. 2016;8:93–107. doi:10.2147/BCTT.S69488
   PubMedGoogle Scholar
• Naher S, Tognela A, Moylan E, Adams DH, Kiely B. Patterns of care and outcomes among triple-negative early breast cancer patients in South Western Sydney. Intern Med J. 2017;48:567–572. doi:10.1111/imj.13628
   Web of Science ®Google Scholar
• Siddharth S, Sharma D. Racial disparity and triple-negative breast cancer in African-American women: a multifaceted affair between obesity, biology, and socioeconomic determinants. Cancer Multidisci Digital Publish Ins. 2018;10(12):1–19. doi:10.3390/cancers10120514
   Google Scholar
• Astvatsaturyan K, Yue Y, Walts AE, Bose S. Androgen receptor positive triple negative breast cancer: clinicopathologic, prognostic, and predictive features. Public Library Sci One. 2018;13(6). doi:10.1371/journal.pone.0197827
   Google Scholar
• Wang DY, Jiang Z, Ben-David Y, Woodgett JR, Zacksenhaus E. Molecular stratification with triple-negative breast cancer subtypes. Sci Rep. 2019;9(19107). doi:10.1038/s41598-019-55710-w
   Google Scholar
• Gortman A, Aherne NJ, Westhuyzen J, et al. Metaplastic carcinoma of the breast: clinicopathological features and treatment outcomes with long-term follow up. Molecul Clin Oncol. 2021;15(178). doi:10.3892/mco.2021.2340
   PubMedGoogle Scholar
• Shingde R, Salindera S, Aherne NJ, et al. Survival outcomes for breast cancer patients who decline recommended treatment: a propensity score-matched analysis. ANZ J Surg. 2021;91:1766–1771. doi:10.1111/ans.16859
   PubMed Web of Science ®Google Scholar
• Hallenstein LG, Sorensen C, Hodgson L, et al. Assessment of genetic referrals and outcomes for women with triple negative breast cancer in regional cancer centres in Australia. Hered Cancer Clin Pract. 2021;19(19). PMID: 33637119. doi:10.1186/s13053-021-00176z
   PubMedGoogle Scholar
• Leung SCY, Nielson TO, Zabaglo L, et al. Analytical validation of a standardized scoring protocol for Ki67: Phase 3 of an international multicenter collaboration. NPJ Breast Cancer. 2016;2(16014). doi:10.1038/npjbcancer.2016.14
   PubMedGoogle Scholar
• American College of Surgeons. American Joint Committee on Cancer (AJCC) cancer staging manual; 2018. Available from: https://cancerstaging.org/referencestools/deskreferences/Documents/AJCC%20Breast%20Cancer%20Staging%20System.pdf. Accessed March 13, 2021.
   Google Scholar
• Roche Diagnostics. VENTANA anti-estrogen receptor (ER) (SP1) rabbit monoclonal primary antibody; 2020. Available from: https://diagnostics.roche.com/us/en/products/product-category/breast-diagnostic-solutions.html. Accessed March 13, 2021.
   Google Scholar
• Roche Diagnostics. VENTANA anti-progesterone receptor (PR) (1E2) rabbit monoclonal primary antibody; 2019. Available from: https://diagnostics.roche.com/us/en/products/productcategory/breast-diagnostic-solutions.html. Accessed March 13, 2021.
   Google Scholar
• Roche Diagnostics. VENTANA anti-HER2/neu (4B5) rabbit monoclonal primary antibody; 2020. Available from: https://diagnostics.roche.com/us/en/products/productcategory/breast-diagnostic-solutions.html. Accessed March 13, 2021.
   Google Scholar
• Marque C. Anti-androgen receptor (SP107) rabbit monoclonal primary antibody; 2017. Available from: https://www.cellmarque.com/antibodies/CM/2126/Androgen-Receptor_SP107. Accessed March 13, 2021.
   Google Scholar
• Allison KH, Hammond MEH, Dowsett M, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol. 2020;38:1346–1366. doi:10.1200/JCO.19.02309
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice guideline focused update. Arch Pathol Lab Med. 2018;142:1364–1382. doi:10.5858/apra.2018-0902-SA
   PubMed Web of Science ®Google Scholar
• Kumar V, Yu J, Phan V, Tudor IC, Peterson A, Uppal H. Androgen receptor immunohistochemistry as a companion diagnostic approach to predict clinical response to enzalutamide in triple-negative breast cancer. J Clin Oncol. 2017;1:1–19. doi:10.1200/PO.17.00075
   Google Scholar
• Bronte G, Bravaccini S, Ravaioli S, et al. Androgen receptor expression in breast cancer: what differences between primary tumor and metastases? Transl Oncol. 2018;11(14):950–956. doi:10.1016/j.tranon.2018.05.006
   PubMedGoogle Scholar
• Bravaccini S, Ravaioli S, Amadori D, et al. Are there differences in androgen receptor expression in invasive breast cancer in African (Tanzanian) population in comparison with the Caucasian (Italian) population? Front Endocrinol. 2018;9(137):1–6. doi:10.3389/fendo.2018.00137
   PubMedGoogle Scholar
• Wen S, Manuel L, Doolan M, Westhuyzen J, Shakespeare TP, Aherne NJ. Effect of clinical and treatment factors on survival outcomes of triple negative breast cancer patients. Dovepress. 2020;12:27–35. doi:10.2147/BCTT.S236483
   Google Scholar
• Narayanan R, Dalton JT. Androgen receptor: a complex therapeutic target for breast cancer. Cancer Multidisci Digital Publish Ins. 2016;8(12):1–17. doi:10.3390/cancers8120108
   Google Scholar
• Venema CM, Bense RD, Steenbruggen TG, et al. Consideration of breast cancer subtype in targeting the androgen receptor. Pharmacol Ther. 2019;200:135–147. doi:10.1016/j.pharmathera.2019.05.005
   PubMed Web of Science ®Google Scholar
• Anestis A, Zoi I, Papavassiliou AG, Karamouzis MV. Androgen receptor in breast cancer - clinical and preclinical research insights. MDPI. 2020;25(2):1–11. doi:10.3390/molecules25020358
   Google Scholar
• Gerratana L, Basile D, Buono G, et al. Androgen receptor in triple negative breast cancer: a potential target for the targetless subtype. Cancer Treat Rev. 2018;68:102–110. doi:10.1016/j.ctrv.2018.06.005
   PubMed Web of Science ®Google Scholar
• Teoh PY, Tan GC, Mahsin H, Wong YP. Androgen receptor expression in triple negative breast carcinoma and its association with the clinicopathological parameters. Malays J Pathol. 2019;41(2):125–132.
   PubMed Web of Science ®Google Scholar
• Sunar V, Dogan HT, Sarici F, et al. Association between androgen receptor status and prognosis in triple negative breast cancer. JBUON. 2018;23(5):1325–1330.
   Google Scholar
• McGhan LJ, McCullough AE, Protheroe CA, et al. Androgen receptor-positive triple negative breast cancer: a unique breast cancer subtype. Ann Surg Oncol. 2014;21(2):361–367. doi:10.1245/s10434-013-3260-7
   PubMed Web of Science ®Google Scholar
• Wang C, Pan B, Zhu H, et al. Prognostic value of androgen receptor in triple negative breast cancer: a meta-analysis. Oncotarget. 2016;7(29):46482–46491. doi:10.18632/oncotarget.10208
   PubMedGoogle Scholar
• Liu YX, Zhang KJ, Tang L. Clinical significance of androgen receptor expression in triple negative breast cancer-an immunohistochemistry study. Oncol Lett. 2018;15(6):10008–10016. doi:10.3892/ol.2018.8548
   PubMed Web of Science ®Google Scholar
• Riaz N, Idress R, Habib S, Lalani E. Lack of androgen receptor expression selects for basal-like phenotype and is a predictor of poor clinical outcome in non-metastatic triple negative breast cancer. Front Oncol. 2020;10:1–14. doi:10.3389/fonc.2020.01083
   PubMed Web of Science ®Google Scholar
• Jam S, Abdollahi AZ, Khazaeipour Z, Omranipour R, Najafi M. Androgen receptor expression in triple-negative breast cancer. androgen receptor expression in triple-negative breast cancer. Arch Breast Cancer. 2019;6(2):90–94. doi:10.32768/abc.20196292-95
   Google Scholar
• Payandeh M, Shazad B, Madani SH, Ramezani M, Sadeghi M. Androgen receptor expression and its correlation with other risk factors in triple negative breast cancers: a report from Western Iran. Asian Pac J Cancer Prev. 2016;17(7):3321–3324.
   PubMedGoogle Scholar
• Cabezas-Quintario MA, Zenzola V, Arguelles M, Perez-Fernandez E. Androgen receptor as prognostic marker in triple-negative breast cancer patients. J Med Surg Pathol. 2018;3(4):1–6. doi:10.4172/2472-4971.1000170
   Google Scholar
• Lyalkin SA, Verevkina NO, Alekseyenko OO, Syvak LA. Prognostic role of androgen receptor expression in patients with metastatic triple negative breast cancer. Exp Oncol. 2020;42(2):140–143. doi:10.32471/exp-oncology.2312-8852.vol-42-no-2.14579
   PubMedGoogle Scholar
• Zakaria F, El-Mashad N, Mohamed D. Androgen receptor expression as a prognostic and predictive marker in triple-negative breast cancer patients. Alexandria J Med. 2016;52(2):131–140. doi:10.1016/j.ajme.2015.06.002
   Web of Science ®Google Scholar
• Soliman NA, Yussif SM. Ki-67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496–504. doi:10.20892/j.issn.2095-3941.2016.0066
   PubMed Web of Science ®Google Scholar
• Hu XQ, Chen WL, Ma HG, Jiang K. Androgen receptor expression identifies patient with favorable outcome in operable triple negative breast cancer. Oncotarget. 2017;8(34):56364–56374. doi:10.18632/oncotarget.16913
   PubMedGoogle Scholar
• James M, Dixit A, Robinson B, Frampton C, Davey V. Outcomes for patients with non-metastatic triple-negative breast cancer in New Zealand. Clin Oncol. 2019;31(1):17–24. doi:10.1016/j.clon.2018.09.006
   Web of Science ®Google Scholar
• O’Rorke M, Murray LJ, Brand J, Bhoo-Pathy N. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: a systematic review and meta-analysis of 5507 patients. Cancer Treat Rev. 2016;47:12–21. doi:10.1016/j.ctrv.2016.05.001
   PubMed Web of Science ®Google Scholar
• Gonçalves H, Guerra MR, Duarte Cintra JR, Fayer VA, Brum IV, Bustamante Teixeira MT. Survival study of triple-negative and non-triple-negative breast cancer in a Brazilian cohort. Clin Med Insights. 2018;12. doi:10.1177/1179554918790563
   Google Scholar
• Chen SS, Tang SC, Li K, et al. Predicting the survival of triple-negative breast cancer in different stages: a SEER population based research referring to clinicopathological factors. Cancer Invest. 2020;38(10):549–558. doi:10.1080/07357907.2020.1831010
   PubMed Web of Science ®Google Scholar
• Asano Y, Kashiwagi S, Goto W, et al. Expression and clinical significance of androgen receptor in triple-negative breast cancer. Cancer Multidisci Digital Publish Ins. 2017;9(1). doi:10.3390/cancers9010004
   Google Scholar
• Kneubil MC, Godoy AEG, Coelho GP, et al. Androgen receptor expression in triple negative breast cancer and its relationship to prognostic factors. Mastology. 2017;27(3):199–205. doi:10.5327/Z2594539420170000205
   Google Scholar
• Adamo B, Ricciardi GRR, Ieni A, et al. The prognostic significance of combined androgen receptor, E-Cadherin, Ki67 and CK5/6 expression in patients with triple negative breast cancer. Oncotarget. 2017;8(44):76974–76986. doi:10.18632/oncotarget.20293
   PubMedGoogle Scholar
• Tzikas AK, Nemes S, Linderholm BK. A comparison between young and old patients with triple-negative breast cancer: biology, survival and metastatic patterns. Breast Cancer Res Treat. 2020;182(3):643–654. doi:10.1007/s10549-020-05727-x
   PubMed Web of Science ®Google Scholar
• Balkenhol MCA, Vreuls W, Wauters CAP, Mol SJJ, van der Laak JAWM, Bult P. Histological subtypes in triple negative breast cancer are associated with specific information on survival. Ann Diagn Pathol. 2020;46. doi:10.1016/j.anndiagpath.2020.151490
   PubMed Web of Science ®Google Scholar
• Sanges F, Floris M, Cossu-Rocca P, et al. Histologic subtyping affecting outcome of triple negative breast cancer: a large Sardinian population-based analysis. BioMed Central Cancer. 2020;20(1). doi:10.1186/s12885-020-06998-9
   Google Scholar
• Bhattarai S, Klimov S, Mittal K, et al. Prognostic role of androgen receptor in triple negative breast cancer: a multi-institutional study. Cancers. 2019;11(7):995. doi:10.3390/cancers11070995
   PubMed Web of Science ®Google Scholar
• Ricciardelli C, Bianco-Miotto T, Jindal S, et al. The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Am Associ Cancer Res. 2018;24(10):2328–2341. doi:10.1158/1078-0432.CCR-17-1199
   PubMed Web of Science ®Google Scholar
• Escala-Garcia M, Morra A, Canisius S, et al. Breast cancer risk factors and their effects on survival: a Mendelian randomisation study. BioMed Central Med. 2020;18(1). doi:10.1186/s12916-020-01797-2
   Google Scholar
• Kensler KH, Regan MM, Heng YJ, et al. Prognostic and predictive value of androgen receptor expression in postmenopausal women with estrogen receptor-positive breast cancer: results from the Breast International Group Trial 1-98. Breast Cancer Res. 2019;21(1). doi:10.1186/s13058-019-1118-z
   PubMedGoogle Scholar
• Giovannelli P, Di Donato M, Auricchio F, Castoria G, Migliaccio A. Androgens induce invasiveness of triple negative breast cancer cells through AR/Src/PI3-K complex assembly. Sci Rep. 2019;9(1). doi:10.1038/s41598-019-41016-4
   PubMedGoogle Scholar